K

B

Bill & Melinda Gates Foundation

Crunchbase
Pitchbook
Crunchbase

Deals on record

12

Common Fundraising Type

Non-dilutive financing

S
Synvect

Biotechnology • CRISPR

Redbud logo
NuFund logo
Bill & Melinda Gates Foundation logo
Antler logo

Synvect is a biotechnology company that develops CRISPR-based technology to control mosquito populations by producing sterile male mosquitoes to suppress disease transmission.

Seed
$3M
03/11/2025
Article
S
Salience Labs

Photonic solutions • AI datacenter connectivity

ICM HPQC Fund logo
Oxford Sciences Enterprises logo
Silicon Catalyst logo
Cambridge Innovation Capital logo

Salience Labs develops photonic solutions, specifically optical switches, to enhance AI datacenter connectivity.

Series A
$30M
02/07/2025
Article
O
Owlstone Medical

Breath-based diagnostics • Early disease detection

Ventura Capital logo
Aviva Ventures logo
Horizons Ventures logo
Gates Foundation logo

Owlstone Medical develops breath-based diagnostic tests and point-of-care devices for early disease detection and precision medicine.

Series E
$26.8M
01/15/2025
Article
A
Aptitude Medical Systems

Molecular diagnostics • Point of Care

Bill & Melinda Gates Foundation logo

Aptitude Medical Systems develops the Metrix® molecular diagnostics platform for affordable Point of Care and Over-The-Counter testing of sexually transmitted infections.

Non-dilutive financing
$10M
01/06/2025
Article
B
BioSurfaces

Biotherapeutics • Chronic Illness

Bill and Melinda Gates Foundation logo

BioSurfaces develops nanofiber-based devices for the long-term delivery of biotherapeutic agents to treat chronic illnesses.

Non-dilutive financing
$2M
11/25/2024
Article
F
Freya Biosciences

Biotech • Women's Reproductive Health

Bill and Melinda Gates Foundation logo
Denmark logo

Freya Biosciences is a biotech company advancing women's reproductive health through the development of vaginal microbial immunotherapeutics for infertility associated with dysbiotic vaginal microbiota in patients undergoing assisted reproductive technology.

Equity
$11.8M
11/19/2024
Article
P
PopVax

Biotechnology • MRNA

Bill & Melinda Gates Foundation logo

PopVax is an Indian biotechnology company developing thermostable mRNA delivery systems for vaccines, with a focus on creating a next-generation COVID-19 vaccine.

Non-dilutive financing
$1.1M
10/30/2024
Article
R
Radiant Bio

Multabody™ platform • Oncology

Amplitude Ventures logo
Toronto Innovation Acceleration Partners logo
FACIT logo
Bill & Melinda Gates Foundation logo

Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.

Series A
$35M
09/11/2024
Article
N
Naobios

CDMO • Viral Vaccines

Bill & Melinda Gates Foundation logo

Naobios is a French contract development and manufacturing organization (CDMO) that specializes in creating and producing viral vaccines and vectors, and is currently focused on enhancing vaccine development and effectiveness evaluation with the support of a grant from the Bill & Melinda Gates Foundation.

Non-dilutive financing
$1.9M
12/11/2023
Article
K
Kyron Learning

AI-based learning • Conversational AI technology

Bill & Melinda Gates Foundation logo
Owl Ventures logo
Charter School Growth Fund logo
ECMC Group logo

Kyron Learning is an AI-based educational technology company developing a conversational AI platform for K-12 math curriculum, currently piloting its fourth-grade math content in schools with plans for expansion.

Series A
$15.4M
12/05/2023
Article
O
Osmo

Machine Olfaction • AI-Enabled Scent Platform

Bill & Melinda Gates Foundation logo

Osmo is a machine olfaction startup that utilizes AI-enabled scent technology for insect control, with a focus on discovering and producing novel scent molecules to repel, attract, or destroy disease-carrying insects.

Equity
$8.5M
11/08/2023
Article
O
Osmo

Machine Olfaction • AI-Enabled Scent Platform

Bill & Melinda Gates Foundation logo

Osmo is a machine olfaction startup that utilizes AI-enabled scent technology for insect control, with a focus on discovering and producing novel scent molecules to repel, attract, or destroy disease-carrying insects.

Equity
$8.5M
11/08/2023
Article